No Data
Buy Rating on Vericel: Expanding MACI's Market Potential and Sustaining Top-Line Growth
Vericel to Report Second-Quarter 2024 Financial Results on August 1, 2024
CAMBRIDGE, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its
Insider Sale: CFO Mara Joseph Anthony Jr Sells 5,000 Shares of Vericel Corp (VCEL)
A Glimpse Into The Expert Outlook On Vericel Through 4 Analysts
In the latest quarter, 4 analysts provided ratings for Vericel (NASDAQ:VCEL), showcasing a mix of bullish and bearish perspectives.The table below provides a snapshot of their recent ratings,
Truist Financial Upgrades Vericel(VCEL.US) to Buy Rating, Raises Target Price to $57
Truist Financial analyst Richard Newitter upgrades $Vericel(VCEL.US)$ to a buy rating, and adjusts the target price from $29 to $57.According to TipRanks data, the analyst has a success rate of 58.8%
Vericel Is Maintained at Buy by Truist Securities
Vericel Is Maintained at Buy by Truist